All the above evidences seem to have a clinical relevance: Polonikov, studying four moderate-severe COVID-19 cases, found that while the three patients with normal/high plasma levels of GSH recovered rapidly, the one with low GSH levels, high plasma ROS and ROS/GSH ratio experienced the most severe illness and, at the date of publication, was still sick (Polonikov, 2020)
Laboratory Research on AOD-9604 AOD-9604 is primarily studied in preclinical models to investigate fat metabolism
These data strongly suggest the idea that resistance is not only due to a mutation in a target gene but also to a more wide cellular re-organization ranging from proteomic modulations as those observed in cell wall of resistant cells [24], [25] to metabonomic variations as those related to increased levels of intracellular GSH
Some people may experience mild skin sensitivity when first starting glutathione treatments
N-terminal acetylation protects glucagon-like peptide GLP-1-(7-34)-amide from DPP-IV-mediated degradation retaining cAMP- and insulin-releasing capacity
Unlike full-length hGH, AOD-9604 does not bind the growth hormone receptor and has shown no measurable effect on IGF-1 levels, glucose homeostasis, or somatic growth in the published preclinical literature